Coherus Oncology, Inc.
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Coherus Oncology, Inc.
- Company name
- Coherus Oncology, Inc.
- Organisation type
- Industry
- Registered legal name
- COHERUS ONCOLOGY, INC.
- US industry code (SIC)
- Biological products, (no disgnostic substances)
- Registry sponsor category
- Industry
- SEC filer number (CIK)
- 0001512762
- Legal Entity Identifier (LEI)
- 5493007IL8W5MV932D26
Related records
Trials (27)
- A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
- A Long Term Safety Extension Study (CHS-0214-05)
- A Study of CHS-1000 in Participants With Advanced or Metastatic Solid Tumors
- A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
- A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
- An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
- Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®
- Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
- Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)
- Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)
- Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis
- Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)
- Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
- Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
- Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
- PDT For Induction Therapy For Head And Neck Cancer
- STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
- Study of CHS-114 in Participants With Advanced Solid Tumors
- Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors